BioCryst Reports ZENITH-1 Results With Oral BCX7353 Which Confirm Rapid Onset of Action, Sustained Activity and Robust Dose Response for Treatment of Acute HAE Attacks

Author's Avatar
Feb 23, 2019
Article's Main Image

Based on ZENITH-1 data, company plans to commence Phase 3 trial of single-dose 750 mg oral BCX7353 for acute treatment of hereditary angioedema (HAE) attacks in summer 2019—